文献速递临床试验与 GCP流行病学与生物统计

药物研发与监管评估中估计目标(estimand)的叙述性综述:旧瓶装新酒?

A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
PubMed 文献 · Trials · 2020-07-23

该综述系统评估了欧洲药品管理局(EMA)疾病指南、申办方试验文档及监管问题中估计目标(estimand)及其伴发事件策略的应用现状。结果显示,指南中最常推荐治疗策略,但申办方文档中假想策略应用最多,提示监管目标估计与实际估计不完全一致,主要因伴发事件数据收集受限。

要点

  • 指南中治疗策略推荐占38%,但申办方文档中假想策略应用达74%。
  • 伴发事件策略在指南中出现于53%,申办方文档全部包含,监管问题中44%。
  • 需在设计阶段和申报资料中更明确定义估计目标。

核心结论

  • 估计目标属性存在于指南、申办方文档和监管问题中,但未以估计目标形式描述。
  • 指南最常推荐治疗策略,而申办方文档中假想策略应用最多,监管目标估计与实际估计不完全一致。
  • 不一致主要因伴发事件数据收集受限,难以支持治疗策略。

研究设计与样本

  • 叙述性综述,系统评估EMA疾病指南、申办方试验文档及监管问题中的估计目标及伴发事件策略。
  • 选取神经系统、肿瘤、心血管疾病和呼吸系统四个治疗领域,评估所有有已批准药物的疾病指南及最近批准药物的文档。

主要发现

  • 治疗策略在13/34(38%)指南中推荐,并在9份相应申办方文档中应用;其中4份为唯一策略,5份伴随其他策略。
  • 假想策略未在指南中推荐,但在25/34(74%)申办方文档中作为主要策略应用。
  • 复合策略在3/34(9%)指南中推荐,并在2份相应申办方文档中伴随其他策略应用。
  • 在治疗策略未在指南中推荐,但在2份申办方文档中应用;主层策略在2份指南中推荐,但未在相应申办方文档中应用。

关键数值与推荐

  • 监管问题中,治疗策略出现2例(6%),假想策略6例(18%),复合策略6例(18%),在治疗策略1例(3%)。

临床怎么用

  • 建议在试验设计阶段明确定义估计目标,并在申报资料和评估报告中贯穿始终。
  • 需加强伴发事件数据的收集,以支持治疗策略的实施。

局限性

  • 仅评估四个治疗领域的指南和最近批准药物的文档,可能不反映所有领域情况。
  • 未报告样本量、P值等统计细节,可能限制结论的普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An estimand defines the target of estimation for a clinical trial through specification of the treatment, target population, variable, population-level summary and of the strategies for intercurrent events. A carefully defined estimand aligns the clinical trial design and analysis with the scientific question of interest and adequately accounts for so-called intercurrent events. The ICH E9(R1) addendum suggests five estimand strategies. We evaluated to what extent current practice in drug development and regulatory assessment fits in the estimand framework. METHODS: We systematically evaluated what estimands, especially what strategies for intercurrent events are advised in European Medicines Agency disease guidelines, used in sponsors' trials and additionally requested by the European Medicines Agency in assessment dossiers. We selected four therapeutic areas: nervous system, oncology, cardiovascular diseases and respiratory diseases. For each, we evaluated all disease guidelines with approved drugs, the dossiers of the most recently approved drugs matching the guidelines and corresponding regulatory questions. RESULTS: Strategies for intercurrent events were present in 18 (53%) of 34 guidelines, in all 34 sponsor documentations and in 15 (44%) of 34 sets of regulatory questions. Treatment policy was advised in 13 (38%) guidelines and was applied in 9 corresponding sponsor documentations. Of these 9, it was the sole strategy in 4 cases and accompanied by another strategy in 5 cases. Hypothetical strategy was not advised in guidelines. However, it was the leading strategy applied in 25 (74%) sponsor documentations. Composite strategy was advised in 3 (9%) guidelines and applied accompanied by another strategy in 2 corresponding sponsor documentations. While on treatment strategy was not advised in guidelines, but was applied in 2 sponsor documentations. Principal stratum strategy was advised in 2 guidelines but not applied in corresponding sponsor documentations. Of the regulatory questions, treatment policy was present in 2 cases (6%), hypothetical in 6 cases (18%), composite in 6 cases (18%) and while on treatment in 1 case (3%). CONCLUSIONS: Estimand attributes are present in guidelines, sponsor documentations and regulatory questions, but not described as estimands. Treatment policy was most often advised in guidelines, but hypothetical was the leading strategy applied in sponsor documentations. Thus, results indicate not a full concordance between the regulatory target of estimation and what is actually estimated. The lack of concordance was mostly due to limitations in collection of intercurrent events data to enable a treatment policy strategy. There is, therefore, a need to better define estimands at the design stage and throughout the applications dossiers and assessment reports.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mitroiu M, Oude Rengerink K, Teerenstra S, et al. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels? Trials. 2020. PMID: 32703247. doi:10.1186/s13063-020-04546-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。